Solution for Startups & Biotechs
Services provided for Biotechs have been the cornerstone of
SCiAN's business since 1990, the beginning of the biotech era. Our
portfolio of studies includes more than 350 clinical trials
completed for Startups and mid-size Biotech companies, primarily in
North America. Our services included study design, protocol
development, data management (edc, paper, fax), randomization,
medical monitoring, SAE management, DSMBs, interim analyses, final
analyses, safety updates, clinical study reports, and
manuscripts.
Studies completed by SCiAN ranged from small and complex
phase I/II oncology trials to large-scale global II/III trials
managed in collaboration with Sponsor's team and other
clinical / site management CROs and functional service
providers. Our senior consulting team is routinely
asked to participate in strategic planning as members of
Steering Committees, DSMBs, and Clinical Advisory Boards. In this
capacity - as a true "Biotech CRO" - we are asked to plan and
analyze pharmacokinetic and pharmacodynamic studies / data
(clinical or preclinical), re-analyze or design
new preclinical toxicity studies.
We believe, SCiAN's new business model of
"subscription based EDC studies" complemented with our scalable
services offering of:
- Level 1: Data is Fully managed by Sponsor / CROs
- Level 2: Selected data management tasks done by SciAn
on demand (backup function)
- Level 3: Full service data management, biostatistics, and
reporting services by SciAn(a full service model)
offers the desired flexibility many of our clients seek in their
early-stage drug development programs.